These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
332 related items for PubMed ID: 3161601
1. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)]. Doudet D, Gross C, Lebrun-Grandié P, Bioulac B. C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601 [Abstract] [Full Text] [Related]
2. Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data. Doudet D, Gross C, Lebrun-Grandie P, Bioulac B. Electromyogr Clin Neurophysiol; 1986 Dec; 26(8):711-27. PubMed ID: 3493894 [No Abstract] [Full Text] [Related]
3. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992 [Abstract] [Full Text] [Related]
11. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease]. Lange KW. Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447 [Abstract] [Full Text] [Related]
12. Metabolic mapping of the oculomotor system in MPTP-induced parkinsonian monkeys. Ho VW, Porrino LJ, Crane AM, Burns RS, Kopin IJ, Sokoloff L. Ann Neurol; 1988 Jan; 23(1):86-9. PubMed ID: 3257855 [Abstract] [Full Text] [Related]
15. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors. Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T. Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115 [Abstract] [Full Text] [Related]
17. Adrenal medulla and Parkinson's disease. Stoddard SL, Merkel GJ, Cook JA, Zinsmeister AR, Carmichael SW. Microsc Res Tech; 1994 Oct 01; 29(2):151-4. PubMed ID: 7812036 [Abstract] [Full Text] [Related]
18. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys. Miyoshi Y, Zhang Z, Ovadia A, Lapchak PA, Collins F, Hilt D, Lebel C, Kryscio R, Gash DM. Ann Neurol; 1997 Aug 01; 42(2):208-14. PubMed ID: 9266731 [Abstract] [Full Text] [Related]
19. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Kurlan R, Kim MH, Gash DM. Mov Disord; 1991 Aug 01; 6(2):111-8. PubMed ID: 2057003 [Abstract] [Full Text] [Related]
20. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T. Parkinsonism Relat Disord; 2009 Jul 01; 15(6):445-52. PubMed ID: 19196540 [Abstract] [Full Text] [Related] Page: [Next] [New Search]